Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Thai FDA Category Presentation/Packing

Full Prescribing Info

Indications/Uses

Xtandi is indicated: as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage-radiotherapy (see Pharmacology: Pharmacodynamics under Actions); for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) (see Pharmacology: Pharmacodynamics under Actions); for the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see Pharmacology: Pharmacodynamics under Actions); for the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see Pharmacology: Pharmacodynamics under Actions); for the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.

Xtandi Indications/Uses

enzalutamide

Manufacturer:

Catalent Pharma Solutions

Distributor:

Zuellig Pharma

Marketer:

Astellas Pharma